Join Renew Roaring Fork for a talk with Dr. Tim Boyd, Department of Neurology at the University of Colorado Anschutz School of Medicine on how he is investigating new and innovative ways to treat Alzheimer’s Disease and other neurodegenerative diseases through the application of Leukine, a drug formerly used for Rheumatoid Arthritis. This particular research effort has been said to have incredible potential for people living with Alzheimer’s Disease (and other neurodegenerative diseases) and their families. He will compare this various approaches to combatting neurodegeneration, including those of lifestyle modifications.
Time/Event Details: November 14th, 5:00-7:30 pm Cocktails and appetizers Reception from 5:00-6:00pm, speaker from 6:00-7:30pm
Timothy Boyd, PhD, MSB, is a Faculty Research Instructor in the laboratory of Dr. Huntington Potter within the Department of Neurology and the Linda Crnic Institute for Down Syndrome at the University of Colorado Anschutz School of Medicine. Dr. Boyd received a Master in Biotechnology and a PhD in Medical Sciences at the University of South Florida, researching the mechanisms that underlie the inverse relationship between Rheumatoid arthritis (RA) and Alzheimer’s disease (AD), in which the vast majority of individuals with RA do not tend to develop AD. His research identified a factor, increased in RA, that rapidly reversed AD pathology and cognitive impairment in models of AD, and found that the human version of this factor, commercially known as Leukine®/sargramostim , was also associated with improved cognition in cancer patients who acquire cognitive impairment from their chemotherapy treatments. This research has led to ongoing clinical trials of Leukine® within mild-to-moderate AD subjects at the University of Colorado Anschutz Medical Campus (NCT01409915) and in Mild Cognitive Impaired (MCI) subjects at Baylor Medical School in Houston, Texas (NCT02667496). Currently, he is working to help establish a state-of-the-art biorepository for the Rocky Mountain Alzheimer’s Disease Center, to study biomarkers from blood samples of adults with Down Syndrome, MCI, AD, and normal aging subjects at the University of Colorado Hospital Memory Disorder Clinic, and to investigate mechanisms of Traumatic Brain Injury (TBI) that cause it to be a risk factor for AD and Chronic Traumatic Encephalopathy. Additionally, Dr. Boyd is an investigator on a Cerebral Palsy Adult Transition Longitudinal Study (NCT02137005) to study blood biomarkers from samples of subjects with Cerebral Palsy at Children’s Hospital Colorado.